Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabotegravir/rilpivirine - Johnson & Johnson Innovative Medicine/ViiV Healthcare

Drug Profile

Cabotegravir/rilpivirine - Johnson & Johnson Innovative Medicine/ViiV Healthcare

Alternative Names: CAB LA + RPV LA combination therapy; CABENUVA; Cabotegravir and rilpivirine extended release injectable suspensions; Cabotegravir plus rilpivirine combination therapy; GSK 1265744 plus rilpivirine combination therapy; GSK 1265744 plus TMC 278 combination therapy; Long-acting cabotegravir plus long-acting rilpivirine combination therapy

Latest Information Update: 06 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Pharmaceuticals; ViiV Healthcare
  • Developer GSK; Johnson & Johnson Innovative Medicine; National Institute of Allergy and Infectious Diseases; ViiV Healthcare
  • Class Antiretrovirals; Benzonitrile; Fluorobenzenes; Nitriles; Oxazoles; Pyrazines; Pyridones; Pyrimidines; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 06 May 2024 Launched for HIV-1 infections (Treatment-experienced) in USA (IM)
  • 06 Mar 2024 Efficacy and adverse events data from the phase III LATITUDE trial in HIV-1 infections were released by ViiV Healthcare
  • 03 Mar 2024 Efficacy data from the phase IIIb SOLAR trial in HIV-1 infections presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024 (CROI-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top